Rhythm* Initiates Phase 2b Clinical Trial of Relamorelin for Diabetic Gastroparesis
04/08/15
Rhythm* Appoints Fred T. Fiedorek, M.D., Chief Medical Officer
12/11/14
Rhythm* Presents Positive Phase 2 Study Results for Relamorelin for Chronic Constipation
10/24/14
Actavis Signs Option to Acquire Rhythm Subsidiary* and its GI Development Product, Relamorelin
10/22/14
Rhythm* Files Registration Statement for Proposed Initial Public Offering
08/27/14
Rhythm* to Present at the Cowen and Company 34th Annual Health Care Conference
02/28/14
Rhythm* Announces Study Demonstrating High Prevalence of Diabetic Gastroparesis Symptoms in the U.S.
05/20/13
Rhythm* Expands Series B Financing to $33 Million; Adds Pfizer Ventures as an Investor
11/27/12
Rhythm* Announces Positive Phase 1 Results for Ghrelin Prokinetic RM-131
10/22/12
Rhythm* Raises $25M in Series B Financing for Diabetes and Obesity Therapeutics
06/13/12
Rhythm* Initiates Phase 2 Clinical Trial of Ghrelin Prokinetic RM-131 for Diabetic Gastroparesis
06/06/12
Rhythm* Announces Phase 1b Results for Ghrelin Prokinetic RM-131 for Diabetic Gastroparesis
05/22/12
Rhythm* Names Lex Van der Ploeg Chief Scientific Officer
11/30/11
Rhythm* Names Keith M. Gottesdiener Chief Executive Officer
11/09/11
Rhythm* Expands Scientific Advisory Board for Clinical Programs in Metabolic Diseases
07/26/11
Rhythm’s* RM-131 Restores GI Function as a Potent Ghrelin Prokinetic
05/09/11
Rhythm* Closes $40 Million Series A Financing
09/08/10
Rhythm* Announces $21 Million Series A
03/15/10
